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Alkaline phosphatase (ALP) is important in calcification and its expression seems to be associated with the inflammatory
process. We investigated the in vitro acute effects of compounds used for the prevention or treatment of cardiovascular diseases
on total ALP activity from male Wistar rat heart homogenate. ALP activity was determined by quantifying, at 410 nm, the p-
nitrophenol released from p-nitrophenylphosphate (substrate in Tris buffer, pH 10.4). Using specific inhibitors of ALP activity and
the reverse transcription-polymerase chain reaction, we showed that the rat heart had high ALP activity (31.73 ± 3.43 nmol p-
nitrophenol·mg protein-1·min-1): mainly tissue-nonspecific ALP but also tissue-specific intestinal ALP type II. Both ALP
isoenzymes presented myocardial localization (striated pattern) by immunofluorescence. ALP was inhibited a) strongly by 0.5
mM levamisole, 2 mM theophylline and 2 mM aspirin (91, 77 and 84%, respectively) and b) less strongly by 2 mM L-
phenylalanine, 100 µL polyphenol-rich beverages and 0.5 mM progesterone (24, 21 to 29 and 11%, respectively). ß-estradiol and
caffeine (0.5 and 2 mM) had no effect; 0.5 mM simvastatin and 2 mM atenolol activated ALP (32 and 36%, respectively).
Propranolol (2 mM) tended to activate ALP activity and corticosterone activated (18%) and inhibited (13%) (0.5 and 2 mM,
respectively). We report, for the first time, that the rat heart expresses intestinal ALP type II and has high total ALP activity. ALP
activity was inhibited by compounds used in the prevention of cardiovascular pathology. ALP manipulation in vivo may constitute
an additional target for intervention in cardiovascular diseases.
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Introduction
Alkaline phosphatase (ALP; EC 3.1.3.1.; orthophos-
phoric-monoester phosphohydrolase, alkaline optimum)
is ubiquitous in nature (from bacteria to humans); however,
its physiological role and natural substrates remain largely
unknown (1,2). The first established function of ALP is its
role in bone mineralization (1-3). More recently, it has been
proposed that ALP regulates lipid transport (4). ALP ex-
pression in vascular endothelia of small arterioles in the
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brain and heart, which normally do not mineralize, could
contribute to vascular hardening and calcification that could,
in turn, be related to vascular aging and vascular disease
(1,5).
Vascular calcification, including coronary artery calcifi-
cation and aortic valve calcification, is a common and
clinically significant component of atherosclerosis and car-
diac valvular disease. The amount of coronary calcification
correlates with the overall coronary plaque burden and an
increased risk of myocardial infarction. The degree of
aortic valve calcification is a strong predictor of both the
progression and the outcome of aortic stenosis. These
calcified lesions contain not only various components as-
sociated with bone mineralization, such as ALP, but also
inflammatory cells such as macrophages and lympho-
cytes. Although the mechanisms underlying valve calcifi-
cation have not been established, recent data suggest that
valve calcification is an active process, much like athero-
sclerosis, that is preceded by inflammation, lipid deposi-
tion and the accumulation of extracellular bone matrix
proteins (1,6-11).
ALP represents a family of phosphomonoesterases,
which, in humans, are expressed by four different gene
loci : tissue-nonspecific (Tn-ALP), intestinal (Int-ALP), pla-
cental (P-ALP) and germ-cell isoenzymes (Gc-ALP) (2).
Tn-ALP is present in a large number of tissues (mainly
located in the external side of plasma membranes via a
glycosyl-phosphatidylinositol anchor linkage) and is most
abundant in liver, kidney and bone. Int-ALP, P-ALP and
Gc-ALP are tissue-specific ALPs (Ts-ALP). Ts-ALPs are
named for the tissue with highest expression and activity
(none are expressed in just one tissue). Only humans and
great apes have P-ALP; all other mammals have instead
Int-ALP (2,12). Tissue differential processing of each of the
ALP gene products, for example through differential glyco-
sylation, gives rise to tissue-specific isoforms (2,13). De-
pending on the physiological/pathological conditions ALP
can be released into intestinal lumen, plasma or bile in
various isoforms: with or without its anchor and in the
former case associated or not with membrane fragments
(2). ALP isoenzymes (and isoforms) can be distinguished
by their heat stability, optimum pH, substrate affinity or
effect of several specific inhibitors or activators (2,13-19).
The variety of ALP forms led our group to characterize
the effect (in vitro and/or in vivo) of several endogenous
metabolites, drugs, hormones, beverages and food com-
ponents on ALP isoenzyme and/or isoform activity and/or
expression. In vitro data from our group regarding ALP
activity modulation will be presented shortly in the discus-
sion of this article, since some of our previous results will be
useful for comparison with the present data (13,14,17-19).
In order to further clarify the physiological role of ALP,
we have determined in vitro the acute effect of compounds,
drugs, hormones and polyphenol-rich beverages, with re-
ported cardiovascular protective effects (for the prevention
or treatment of cardiovascular diseases) and/or known
effects on ALP activity from other sources (cell lines,
tissues and species) on total ALP activity from rat heart.
We hypothesize that the modulation of ALP activity may be
another process contributing to explain the protection given
by aspirin, steroid hormones, statins, ß-blockers and
polyphenol-rich beverages against cardiovascular dis-
eases.
Material and Methods
Beverages and their preparation
Lager-type beer (SuperBock®), stout-type beer (Super-
Bock Stout®) and alcohol-free beer (Cheers®) were pur-
chased at the local market (Portuguese beers produced by
UNICER, Portugal). Green and black teas (both from
Tetley®) were also from the local market. Red wine (Vinha
das Garças®) was produced in Palmela region (Terras do
Sado, South of Portugal) by UNICER and provided to us by
this company. Green and black teas were prepared ac-
cording to the recommendations of supplier, by infusing
one tea bag (green tea: 1.75 g for 5 min; black tea: 1.5 g for
2 min) in 250 mL boiling water. Gas was removed from
beers before use. All beverages were used at pH 10.4.
Animals
Sixteen male adult Wistar rats (free from liver and bone
diseases, purchased from Harlan Interfauna Ibèrica,
Barcelona, Spain), weighing 300-340 g, were used. The
animals were maintained under controlled environmental
conditions (12-h light/dark cycle, at 24°C room tempera-
ture), in groups of 3, fed a suitable commercial diet (Harlan)
with water ad libitum. Animal procedures were according
to the European Community guidelines (86/609/EEC) and
the Portuguese Act (129/92) for the use of experimental
animals [the corresponding author holds a Portuguese
authorization for working with laboratory animals (accord-
ing to category C of the recommendations of the Federa-
tion of European Laboratory Animal Science Associa-
tions)]. Animals were anesthetized with pentobarbital (60
mg/kg) and the heart was perfused in situ with ice-cold
isotonic NaCl to wash out blood. The organ was then
removed and rinsed in ice-cold isotonic NaCl. For reverse
transcription-polymerase chain reaction (rt-PCR) analy-
sis, a segment from the left ventricle was rinsed with
diethylpyrocarbonate-water and stored at -80°C until the
moment of the experiment. Rat heart was frozen at -80°C
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until the immunofluorescence experiment. Rat heart was
placed in two times (mL/g) homogenization solution [phos-
phate-buffered saline (PBS, pH 7.4) + 0.5% Triton X-100;
4:1], with no homogenization or other form of cell disrup-
tion, and stored at -80°C until the moment of ALP activity
assay performance.
Reverse transcription-polymerase chain reaction
All molecular biology reagents used were purchased
from Sigma (Sigma Alcobendas, Spain) unless otherwise
stated. After total RNA extraction with Tripure® (Roche,
Germany), 20 µg total RNA was incubated at 37°C for 30
min with 23 units of RNase-free DNase I in 100 µL 5 mM
MgCl2, 50 mM triethanolamine-HCl, pH 7.5, to degrade
any residual DNA. The RNA was extracted with phenol-
chloroform, precipitated with ethanol and dissolved in wa-
ter. For cDNA synthesis, 5 µg of the RNA thus prepared
was incubated at 45°C for 1 h in a total volume of 20 µL with
200 units of Superscript™ II Reverse Transcriptase (RT;
Gibco BRL, Life Technologies, Gaithersburg, MD, USA), in
10 µM random hexamers, 0.375 mM per dNTP, 3 mM
MgCl2, 75 mM KCl, 50 mM Tris-HCl, pH 8.3 (25°C), 10 mM
dithiothreitol and 40 units RNase inhibitor (RNaseOUT™;
Gibco BRL). For paired negative controls RT was omitted.
Following heat-inactivation of the proteins (10 min at 95°C)
and addition of 5 µL 0.5 mg/mL DNase-free RNase A in 10
mM Tris-HCl, pH 8.0, and 50% (v/v) glycerol, the cDNA
was incubated at 37°C for 30 min to degrade unreacted
mRNA. PCR was performed on 4 µL of this preparation.
The PCR product mixture (50 µL) contained 0.5 µM per
primer, 0.2 mM per dNTP, 2.3 mM MgCl2 and 2 units of Taq
DNA polymerase in the buffer provided (Gibco BRL). The
following primers for rat Int-ALP type I, Int-ALP type II, Tn-
ALP and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were used: 5'-CCA GCC AGC TTA CCA ATG
AGA-3' (forward primer Int-ALP type I), 5'-CTG CCT GCT
GCT TGT AGT TGA-3' (reverse primer Int-ALP type I), 5'-
CCT GGA GCC CTA CAC CGA CTG-3' (forward primer
Int-ALP type II), 5'-GCC CCC AGT AGT AGC ATC AGC-3'
(reverse primer Int-ALP type II), 5'-CAG TGT CAG CCG
TTA ATT GAC-3' (forward primer Tn-ALP), 5'-ATC GTG
CTG ACC TTG CCA CA-3' (reverse primer Tn-ALP), 5'-
ACT GGC GTC TTC ACC ACC AT-3' (forward primer
GAPDH), 5'-TCC ACC ACC CTG TTG CTG TA-3' (reverse
primer GAPDH). Thermocycling consisted of 1 cycle of 2
min at 94°C, followed by 35 cycles of 1 min at 94°C, 2 min
at 26°C and 2 min at 72°C for Int-ALP type I, Int-ALP type
II and GAPDH primers or 1 cycle of 2 min at 94°C, followed
by 40 cycles of 0.5 min at 94°C, 0.5 min at 26°C and 1.5 min
at 72°C for Tn-ALP and GAPDH. The predicted sizes (in
bp) of the PCR products were: 249 (Int-ALP type I), 218
(Int-ALP type II), 246 (Tn-ALP) and 682 (GAPDH). Ten
microliters of each individual PCR product was then run on
1.6% agarose gel and visualized with an ultraviolet trans-
illuminator (Vilber Lourmat, France) using ethidium bro-
mide staining, a COHU CCD camera and the appropriate
filters for UV light (Cohu, USA).
Immunofluorescence
The frozen rat heart was included in ornithine carbamyl
transferase solution (Bright, England) and 5-µm thick sec-
tions were cut with a Leica cryostat (Leica Microsystems
GmbH, Germany) and placed onto poly-L-lysine coated
microscopy slides (Polysine™, Menzel-Glaser, Germany).
Immunofluorescence was performed using primary anti-
bodies (Santa Cruz Biotechnology, USA) against Int-ALP
[goat polyclonal antibody (PLAP L-19: sc-15065), diluted
1/25] and Tn-ALP [goat polyclonal antibody (TNAP N-18:
sc-23430), diluted 1/25], for 60 min at room temperature,
after a 10-min blocking period at room temperature [10%
bovine serum albumin (Sigma) w/v in PBS]. PBS was used
instead of the primary antibodies for the negative controls.
Although we have used a polyclonal antibody against P-
ALP and Int-ALP, only Int-ALP was detected since rats do
not express P-ALP (2,5). A 60-min incubation was per-
formed with the secondary antibody (donkey anti-goat
IgG-FITC, sc-2024, from Santa Cruz Biotechnology, di-
luted 1/200) at room temperature. Washings between in-
cubations were performed twice for 5 min each with PBS +
0.1% Tween 20 (Sigma). Antibody dilutions were made
using UltraAb diluent (LabVision Corporation, USA). Nu-
clei counterstaining was achieved with DAPI (4'-6-
diamidino-2-phenylindole, diluted 1/100, Sigma) for 15
min at room temperature. Slides were mounted with
Vectashield (mounting medium for fluorescence; Vector
Laboratories, Inc., USA) and observed with an ApoTome
Microscope (AxioImager.Z1, Zeiss System, Germany), with
a light source of fixed wavelength of 488 and 350 nm, for
IgG-FITC (green) and DAPI (blue), respectively. The
AxionVision 3.0 program (Zeiss) was used to acquire
images and photographs.
Alkaline phosphatase activity
p-Nitrophenylphosphate (p-NPP), p-nitrophenol (p-
NPL), levamisole, L-phenylalanine, theophylline, caffeine,
acetylsalicylic acid, propranolol, atenolol, progesterone,
corticosterone, ß-estradiol and simvastatin were purchased
from Sigma. On the day of ALP quantification, tissue
samples diluted further in homogenization solution (to 1 g
tissue + 12 mL homogenization solution) were homog-
enized and kept on ice. ALP activity assays were carried
out in triplicate, as previously described (13,15). The reac-
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Figure 1. Effect of alkaline phosphatase (ALP) classic inhibitors,
levamisole and L-phenylalanine, on ALP activity from rat heart
homogenate. Results are reported as mean ± SEM and repre-
sent a percent of the corresponding control activity (first column
of each set of results, 100%). The ALP-specific activity in the
control was 31.73 ± 3.43 nmol p-nitrophenol·mg protein-1·min-1.
The horizontal lines indicate significant differences between ef-
fects of inhibitors. *P ≤ 0.005 (paired or unpaired Student t-test).
Figure 2. Detection of Int-ALP type I (Int-ALP-I) and Int-ALP type
II (Int-ALP-II) mRNA in total RNA from rat heart homogenate
using rt-PCR. rt-PCR analysis with specific primers for Int-ALP-I
(lane 1), Int-ALP-II (lane 3) and GAPDH (lanes 1 and 3) was
performed with total RNA prepared from rat heart homogenate
(left ventricle). GAPDH mRNA detection was used as control for
intactness of mRNA. Lanes (+) and (-) correspond to samples
generated in the presence and absence of RT enzyme during
reverse transcriptase reaction, respectively; lanes 2 and 4 corre-
spond to negative controls for Int-ALP-I and Int-ALP-II, respec-
tively. PCR products were separated by agarose gel electropho-
resis, followed by staining with ethidium bromide. GAPDH =
glyceraldehyde-3-phosphate dehydrogenase; Int-ALP = intesti-
nal alkaline phosphatase.
tion mixtures, with a final volume of 500 µL, contained: 80
mM Tris buffer, pH 10.4, 0.4 mM MgCl2, 0.376 mg p-NPP,
the compound (0.1 to 2 mM) or the beverage (50 or 100 µL)
to be tested and heart homogenate. The reactions were
started by the addition of the tissue enzyme sample: 20 µL
heart homogenate in a final dilution of 1/13 in homogeniza-
tion solution. Phosphate concentration in the incubation
medium was 0.353 mM, similarly to other studies by our
group on ALP activity from tissue homogenates (13,15).
Levamisole and L-phenylalanine were dissolved in water.
Theophylline, caffeine and simvastatin were dissolved and
diluted in dimethylsulfoxide. Acetylsalicylic acid (aspirin),
propranolol, atenolol, progesterone, corticosterone and ß-
estradiol were dissolved and diluted in ethanol. Controls
for drugs were run in the presence of a corresponding
volume of solvent. Ethanol 5, 5.6 and 13% solutions were
used as solvent controls for stout-type beer, lager-type
beer and red wine, respectively. Water was used as sol-
vent control for green and black teas. Incubations were
carried out at 37°C for 30 min and the enzymatic reaction
was stopped by adding 2 mL 20 mM NaOH (4°C). The
absorbance of the p-NPL produced by ALP activity was
measured at 410 nm (Spectronic Genesys 5, Milton Roy,
USA). A p-NPL calibration curve was constructed in order
to calculate ALP activity. The effect of each compound or
beverage on ALP activity was calculated as the percent of
the activity of the appropriate ALP control.
Protein determination
Protein concentration was determined as described by
Bradford (20), with bovine serum albumin as standard.
All data are reported as mean ± SEM and represent the
percent of the corresponding control activity (N = number
of cases). The significance of differences between means
was assessed by paired or unpaired Student t-test.
Results
The effect of eleven different compounds (belonging to
different chemical and/or pharmacological classes) and
six different beverages (with high and distinct polyphenol
content) was evaluated on total ALP activity from rat heart
homogenate. Assay conditions allowed linearity of the
enzymatic reaction (data not shown).
Levamisole and L-phenylalanine significantly inhibited
ALP activity from rat heart homogenate, although leva-
misole had a significantly stronger effect (Figure 1). While
0.1 and 0.5 mM levamisole inhibited more than 80% of ALP
activity (in a concentration-dependent way) 2 mM L-phen-
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ylalanine inhibited just 24% of the enzyme activity. Total
ALP-specific activity present in rat heart homogenate was
31.73 ± 3.43 nmol p-NPL·mg protein-1·min-1. As can be
seen in Figure 2, rat heart expresses Int-ALP type II, but
not Int-ALP type I. Both Tn-ALP (Figure 3A) and Int-ALP
(Figure 3B) were expressed in the myocardium; Tn-ALP
clearly showed a striated pattern of distribution.
Theophylline and caffeine had different effects on ALP
from rat heart homogenate: theophylline significantly in-
hibited the enzyme (in a concentration-dependent man-
ner) but caffeine had no effect (Figure 4).
All polyphenol-rich beverages (red wine; lager-type,
stout-type and alcohol-free beers; green and black teas)
tested on ALP activity from rat heart homogenate signifi-
cantly inhibited the enzyme (red wine having the least
volume-dependent pattern of inhibition; Figure 5). Polyphe-
nol-rich beverages had different inhibitory effects on ALP:
50 µL red wine had a significantly stronger effect than the
same volume of stout-type beer or green tea; 50 µL lager-
type beer and 50 µL alcohol-free beer had a significantly
stronger effect than the same volume of green tea (Figure
5).
Aspirin (acetylsalicylic acid, 2 mM) strongly inhibited
ALP activity (84%) from rat heart homogenate (Figure 6);
aspirin effect was concentration-dependent.
Steroid hormones behaved differently towards ALP
activity. ß-estradiol (0.5 and 2 mM) had no effect on enzy-
matic activity. Corticosterone (0.5 mM) activated (18%) but
2 mM corticosterone inhibited (13%) ALP activity. Proges-
terone (0.5 mM) inhibited (11%) ALP activity, with no effect
at 2 mM. At both concentrations, corticosterone effect was
significantly different from that of the other two steroid
hormones (Figure 6).
Simvastatin (0.5 mM) and atenolol (2 mM) significantly
activated (32 and 36%, respectively) ALP activity from rat
Figure 3. Distribution of alkaline phosphatases (ALP) isoen-
zymes in the rat myocardium by immunofluorescence. The pres-
ence of ALP was identified in green, showing a striated pattern
for both isoenzymes, but stronger for tissue-nonspecific ALP.
Cell nuclei were colored in blue with DAPI (4'-6-diamidino-2-
phenylindole). Scale is identical in both figures. A, Tissue-non-
specific ALP. B, Intestinal ALP.
Figure 4. Effect of xanthines (theophylline and caffeine) on
alkaline phosphatase activity from rat heart homogenate. Re-
sults are reported as mean ± SEM and represent a percent of the
corresponding control activity (first column of each set of results,
100%). The horizontal lines indicate significant differences be-
tween effects of xanthines. *P ≤ 0.005 (paired or unpaired Stu-
dent t-test).
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Figure 5. Effect of polyphenol-rich beverages, red wine (13% ethanol), beer [lager-type (5.6% ethanol), stout-type (5.0% ethanol) and
alcohol-free] and tea (green and black) on alkaline phosphatase activity from rat heart homogenate. Results are reported as mean ±
SEM and represent a percent of the corresponding control activity (first column of each set of results, 100%). The horizontal lines
indicate significant differences between effects of polyphenol-rich beverages. *P ≤ 0.05, **P ≤ 0.005 (paired or unpaired Student t-
test).
Figure 6. Effect of acetylsalicylic acid (aspirin), steroid hormones (ß-estradiol, corticosterone and progesterone), simvastatin and ß-
blockers (propranolol and atenolol) on alkaline phosphatase activity from rat heart homogenate. Results are reported as mean ± SEM
and represent a percent of the corresponding control activity (first column of each set of results, 100%). The horizontal lines indicate
significant differences between effects of compounds. *P ≤ 0.05, **P ≤ 0.005 (paired or unpaired Student t-test).
heart homogenate (Figure 6). Atenolol (2 mM) induced a
significantly stronger activation (36%) than 2 mM propran-
olol; propranolol presented a tendency to activate ALP
(effects of both ß-blockers were concentration-dependent;
Figure 6).
Discussion
To our knowledge, this is the first report concerning rat
heart ALP isoenzyme identification (in terms of its mRNA
expression as well as protein localization and percentage
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of activity), total ALP activity quantification in the rat heart
and its in vitro acute modulation by compounds and polyphe-
nol-rich beverages reported in the literature to have cardio-
vascular beneficial effects.
The inhibitory effects of levamisole and L-phenylala-
nine showed that both Tn- and Ts-ALPs were present in rat
heart (with Tn-ALP presenting a greater activity than Int-
ALP), since these compounds are, respectively, specific
inhibitors of these two ALP groups (2,13,19). Our results
are in agreement with those reported by Van Belle (16)
regarding the effects of levamisole and L-phenylalanine on
ALP extracted from normal rat heart (without any treat-
ment). Additionally, we showed, by rt-PCR analysis, that
Int-ALP, namely Int-ALP type II, was indeed expressed in
this tissue.
The rat has two Int-ALP genes (Int-ALP type I and Int-
ALP type II) coding for two Int-ALPs with different primary
structures (79% amino acid homology), temporal postnatal
expression, substrate specificity, tissue localization and
response to fat feeding and to cortisone. After an acute fat
feeding, Int-ALP type II expression is increased in liver
(where Int-ALP type I is not expressed) and Int-ALP type II
expression increases five times more than Int-ALP type I in
the duodenum (4,21,22). It is interesting to note that rat
liver and heart, tissues that can use fat as an energy
source in several physiological states, express the same
Int-ALP gene.
We hypothesized that the high total ALP activity ob-
served in the normal rat heart (without any treatment)
homogenate could not be accounted for only by the pres-
ence of ALP in the vascular compartment and, by immuno-
fluorescence, we showed that both Int- and Tn-ALPs are
present in rat cardiomyocytes, which is in agreement with
our results of total ALP activity in the rat heart and of rat
heart ALP activity inhibition by levamisole and L-phenylal-
anine. Autofluorescence of vascular tissue did not allow us
to visualize ALP in blood vessels. Nevertheless, the pres-
ence of Int-ALP in the human vascular compartment of
different organs has already been reported by Domar et al.
(12) and the presence of Tn-ALP in both the heart vascular
compartment and muscle has already been reported by
Schultz-Hector et al. (5). Müller et al. (23) reported an
increase of ALP activity, after a single injection of iso-
prenaline into the right atrium, particularly on the Schwann
cell and its membranes, membranes enveloping nerve
axons, the sarcolemma of the muscle cell and the fibrocyte
cell surface. These investigators (23) suggested that the
Schwann cell is responsible for the production of ALP.
Here we report the presence of Int-ALP in cardiomyocytes
and the presence of both ALP isoenzymes in normal rat
heart (without any treatment). Although speculative, we
suggest that the distribution of specific fluorescence along
the myofibrils of myocardial cells is compatible with the
presence of ALP in the sarcoplasmic reticulum.
Several lines of evidence suggest ALP as a putative
target for prevention and treatment of cardiovascular dis-
eases. ALP is important for the initiation of calcification and
its inhibition prevents calcification, either normal or ectopic
(1-3,6-8,10,11). ALP activity has been associated with
human valve calcification in vitro and in vivo (7,8,11), with
calcification of bioprosthetic heart valves from bovine peri-
cardium in vitro and in vivo models (10) and with in vitro
sheep aortic valve interstitial cell calcification induced by
transforming growth factor-ß1 (11). These in vitro results
are supported by the rt-PCR studies of gene expression
pattern differences between human calcific aortic stenosis
and human normal aortic valve cusps demonstrating that
calcific aortic cusps have increased ALP and transforming
growth factor-ß1 expression (11). An association between
cardiac valve calcification and inflammation has been re-
ported (9,11,24). ALP seems to be associated with inflam-
matory processes and their modulation/regulation (25,26).
In vitro and in vivo, ALP activity is modulated by oxidative
stress (25,27,28). The ingestion of nutrients/beverages
with anti-oxidant properties has positive effects on cardio-
vascular health (29-31).
In the present study, we sought to understand the
reported “usefulness” of various compounds, hormones
and beverages for prevention and/or treatment of cardio-
vascular diseases. A marked ALP inhibition was observed
with theophylline and aspirin, and some inhibition with
wine, beers and teas. ß-estradiol and caffeine had no
effect; simvastatin and atenolol activated ALP (propranolol
also showing an activation tendency). Corticosterone pre-
sented a mixed behavior on ALP and progesterone slightly
inhibited it.
An inhibitory effect on rat heart ALP activity would be
acceptable as a similar background for the cardioprotec-
tive effects of the compounds, hormones and beverages
tested. By reducing rat heart ALP activity they would con-
tribute to reduce or stop progression of cardiomyocyte,
vascular, valvular and/or aorta calcification improving or
stabilizing the cardiovascular system; however, that did
not occur for all of them. We concluded that only the agents
we have tested with reported preventive effects against
cardiovascular pathology have ALP inhibitory activity. The
meaning of this association is presently unknown but the
importance of cardiovascular diseases strongly recom-
mends further exploration of this link.
Methylxanthines, caffeine and theophylline, have been
included in this study because a) caffeine is probably the
most frequently ingested pharmacologically active sub-
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stance in the world and recent research indicates that
moderate coffee intake may be associated with beneficial
effects on cardiovascular health (32); b) theophylline is
described as an inhibitor of ALP: Tn-ALP isoforms and Ts-
ALP isoenzymes are inhibited/modulated at different de-
grees (13). The theophylline inhibitory effect on rat heart
ALP was similar to its effect on rat kidney cortex ALP but
stronger than that on rat liver ALP (13).
Tea, wine and beer were used in this research because
of their extensive worldwide consumption, anti-oxidant
capacity (related to their polyphenol content) and described
health benefits in preventing cardiovascular diseases (29-
31). The evolution of these pathologies seems to exacer-
bate in estrogen-deficient women, thus, our interest in ß-
estradiol (33). Wine, beer and tea were tested directly in
vitro (in an acute treatment) upon ecto-ALP activity from a
human vascular smooth muscle (AALTR) cell line for the
first time by our group (19). A much stronger inhibitory
effect of these beverages had been observed on AALTR
ecto-ALP activity (19) than on rat heart ALP. These AALTR
results are largely and positively correlated with the polyphe-
nol content of the beverages tested (19,29), what did not
happen in the case of rat heart ALP.
Progesterone, ß-estradiol and/or corticosterone effects
on rat liver and kidney cortex ALP activity as well as on rat
brain microvessel endothelial (RBE4) cell line (13,14) are
different from those presented here. However, similarly to
our present results, in AALTR cell line ß-estradiol had no
effect while corticosterone (and progesterone) activated
the enzyme (18).
Aspirin has been reported to have a protective role in
the cardiovascular system, exhibiting anti-platelet, anti-
thrombotic, anti-inflammatory and anti-oxidant properties.
It also inhibits calcification of bovine pericardium used for
bioprosthetic heart valves (10,34). Our results with aspirin
are in accordance with published data concerning the in
vivo and in vitro effects of aspirin upon ALP activity. Aspirin
inhibits, in vitro and in vivo, the calcium deposition and/or
ALP activity in bioprosthetic heart valves from bovine
pericardium (10). Aspirin, in a therapeutic concentration
range-dependent manner, inhibits ALP secretion and the
stimulatory insulin effect upon ALP production by human
osteoblasts in vitro (35).
It is interesting to note that two drugs sharing anti-
oxidant and anti-inflammatory properties have opposite
effects on rat heart ALP: aspirin and simvastatin (34,36).
Statins have well-known protective effects on cardio-
vascular health, mainly ascribed to their hypolipidemic
activity. Beyond this, statins exert pleiotropic effects on
vascular wall cells, including improvement of endothelial
dysfunction, stabilization of atherosclerotic plaque, de-
crease of oxidative stress and vascular inflammation
(17,36,37). On the other hand, they are reported to in-
crease bone density (17,36). We have recently reported an
increase on ALP activity in rat heart homogenate for
lovastatin (17), but not as intense as with simvastatin.
These ALP activating effects may explain the lack of statin
protection against aortic valve calcification reported by
Cowell et al. (for a discussion of this subject, see Ref. 17).
Simvastatin inhibits rat liver and kidney cortex ALP activity
(17).
ß-blockers are currently used to treat cardiovascular
problems (38) and have been reported to have positive
effects on bone mineralization and/or osteoporosis (39).
The ALP activating effects of propranolol and atenolol
observed here fit well with their putative beneficial effects
on bone.
Epidemiological studies show a positive correlation
between osteoporosis and vascular calcification suggest-
ing that when bone does not mineralize properly the ves-
sels do and vice versa (6). For most of the compounds and
beverages tested there are data about beneficial effects
on bone mineralization and/or osteoporosis (17,30,31,36,
39,40).
Glycosylation can influence/interfere with ALP cata-
lytic activity and ALP activity modulation (2,13,19). Differ-
ential glycosylation of the Tn- and Int-ALPs and/or distinct
level of expression of Tn- and Int-ALPs (assuming their
distinct modulation by the compounds and beverages
tested) can explain the distinct ALP modulation results
obtained with xanthines, polyphenol-rich beverages, ste-
roid hormones and simvastatin on the various cell lines
and/or tissues used so far as ALP sources. Thus, we
concluded that it is fundamental that ALP activity studies
take the enzyme source into account.
To our knowledge this is the first time that ALP was in
vitro acutely treated with aspirin, simvastatin, atenolol and
propranolol (simvastatin results are discussed in Ref. 17),
and there are no data in the literature relating caffeine,
theophylline, ß-blockers (atenolol and propranolol) and
polyphenol-rich beverages (wine, beer and tea) and car-
diomyocyte/vascular/valvular/aorta valve calcification. More
studies, namely involving chronic treatments (measuring
ALP expression and performing mineralization assays)
with these compounds and beverages on cardiovascular
(and bone) tissues or cell lines are needed and strongly
encouraged by our present results.
Both Tn- and Int-ALPs are associated with membrane
surfaces characterized by significant transport activity (1,2,
4,12,14,17,22,23,25). The apparent Tn-ALP localization in
the sarcoplasmic reticulum leads us to raise the hypo-
thesis of ALP being involved in the modulation of the
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crucial transport of Ca2+ across the sarcoplasmic reticulum
membrane, what should be investigated in the future. Also,
evaluation of a putative participation of Int-ALP type II in
lipid transport and deposition in rat heart muscle and
vascular compartment would be interesting, since lipid
deposition contributes to atherosclerosis and Int-ALP is
involved in regulating intestinal lipid transport (4). Further-
more, exploration of this hypothesis (Int-ALP and lipid
transport at the heart) may help to clarify the pathogenesis
of lipid overstorage in cardiac myocytes in type 2 diabetes
mellitus and the development of heart failure and/or the
reduction in triacylglycerol storage and mobilization in
situations of early heart failure.
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